Table 2.
Cost-effectiveness of palliative trastuzumab in breast cancer.
| Study | Year | Origin | Drug costs (US$)* | Survival benefit | Cost-effectiveness (US$)* |
|---|---|---|---|---|---|
| Trastuzumab monotherapy | |||||
| NICE Appraisal34 | 2002 | UK | £5,300 (US$8,255) | 8 months | £19,000 (US$29,293)/QALY |
| Neyt et al35 | 2005 | Belgium | NR | 3.1 months | €47,777 (US$61,780)/LY |
| Trastuzumab plus chemotherapy | |||||
| NICE Appraisal34 | 2002 | UK | £15,500 (US$24,141) | 10 months | £37,500 (US$58,406)/QALY |
| Norum et al36 | 2005 | Norway | €39,454 (US$51,018) | 8.4–3.7 months | €63,137–162,417 (US$81,643–210,021)/LY |
| Poncet et al37–38 | 2008 | France | €14,102 (US$18,235) | 17 months | €15,370 (US$19,875)/LY |
| Perez-Ellis et al39 | 2009 | France | €17,020 (US$22,009) | 18 months | €27,492 (US$35,550)/LY |
| Trastuzumab plus endocrine therapy | |||||
| Fleeman et al40 | 2011 | UK | £35,702 (US$55,606) | 8.0 months | £69,000 (US$107,468)/QALY |
| Trastuzumab beyond progression | |||||
| Matter-Walstra et al41 | 2010 | Swiss | €18,756 (US$24,253) | 5.5 months | €98,329 (US$127,149)/QALY |
Notes:
*
Cost-effectiveness estimates in US$ are presented for comparison purposes only and should not be interpreted as the cost-effectiveness of trastuzumab in the USA. Exchange rates on January 20, 2012 (http://money.cnn.com/data/currencies/index.html).
Abbreviations: LY, Life Year; QALY, Quality Adjusted Life Year; NR, Not Reported; NICE, National Institute of Clinical Excellence.